Prenatal screening platform for risk free early detection of trisomy 21, 18 and 13
CompanyRevvity, Inc., Waltham, USA
The Revvity company offers the Vanadis®-NIPT (non-invasive prenatal test) system for improved and risk-free early detection of genetic diseases in the unborn child. Vanadis enables screening for risk trisomies 21 (Down syndrome), 18 (Edwards syndrome) and 13 (Pätau syndrome), as well as determining the fetal sex by examining cell-free DNA fragments (cfDNA) in the mother's blood. The automated platform takes over all critical work steps. At the beginning, the cfDNA is separated from the plasma and prepared (Vanadis Extract®). The cfDNA fragments are then converted into circular DNA by the Vanadis Core® and marked with chromosome-specific, fluorescent dyes, which are transferred to a microfilter plate (Vanadis View®). Here, the fluorescent DNA fragments are counted using an image analysis algorithm and the results are then transferred to a prenatal screening software (LifeCycle™ 7.0), which assesses the trisomy risk of the respective samples. The method does not require complex PCRs, genome sequencing or microarrays and provides precise predictions within 2–3 days. So far it has been shown that the Vanadis platform has comparable performance in terms of detection and false positive rates with a lower no-call rate compared to NGS (Next Generation Sequencing)-based NIPT systems. In summary, the method enables precise and highly effective prenatal high-throughput screening for relevant genetic diseases, which can help to identify risks to the child's health during pregnancy at an early stage.
Vanadis® NIPT System. A whole new way to NIPT.
www.revvity.com
Added on: 01-11-2024
[1] https://www.revvity.com/de-en/product/vanadis-nipt-system-vanadisivd
